Kroes JA - Search Results

1

Delayed cardiac arrest after hydrofluoric acid ingestion.

Kroes JA, de Haan JMH, de Haan-Lauteslager MI, van Roon EN, Derksen SJ, Manusama ER, Zijlstra GJ, Gisbertz SS, Vrijsen BEL, Bethlehem C. Kroes JA, et al. Clin Toxicol (Phila). 2024 Mar;62(3):205-207. doi: 10.1080/15563650.2024.2328348. Epub 2024 Mar 19. Clin Toxicol (Phila). 2024. PMID: 38501538 No abstract available.

2

Prediction of response to biological treatment with monoclonal antibodies in severe asthma.

Kroes JA, Zielhuis SW, van Roon EN, Ten Brinke A. Kroes JA, et al. Biochem Pharmacol. 2020 Sep;179:113978. doi: 10.1016/j.bcp.2020.113978. Epub 2020 Apr 17. Biochem Pharmacol. 2020. PMID: 32305434 Review.

3

Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report.

Kroes JA, Zielhuis SW, Bethlehem C, Ten Brinke A, Van Roon EN. Kroes JA, et al. Eur J Hosp Pharm. 2022 Jul;29(4):235-236. doi: 10.1136/ejhpharm-2020-002660. Epub 2021 Apr 21. Eur J Hosp Pharm. 2022. PMID: 33883206 Free PMC article.

4

The perceived waning of biologics in severe asthma.

Kroes JA, Van Hal LHG, Van Dijk L, Zielhuis SW, Van Der Meer AN, Van Roon EN, Ten Brinke A. Kroes JA, et al. Respir Med. 2023 Nov-Dec;219:107416. doi: 10.1016/j.rmed.2023.107416. Epub 2023 Sep 25. Respir Med. 2023. PMID: 37757988 Free article.

5

Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics.

Kroes JA, de Jong K, Hashimoto S, Zielhuis SW, van Roon EN, Sont JK, Ten Brinke A. Kroes JA, et al. ERJ Open Res. 2023 Apr 11;9(2):00559-2022. doi: 10.1183/23120541.00559-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 37057095 Free PMC article.

6

Optimizing omalizumab dosing in severe asthma-the exploration of therapeutic drug monitoring.

Kroes JA, Zielhuis SW, van der Meer AN, de Jong K, van Roon EN, Ten Brinke A. Kroes JA, et al. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1408-1410.e1. doi: 10.1016/j.jaip.2020.12.013. Epub 2020 Dec 15. J Allergy Clin Immunol Pract. 2021. PMID: 33338686 Free article. No abstract available.

7

High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study.

Oortgiesen BE, Kroes JA, Scholtens P, Hoogland J, Dannenberg-de Keijzer P, Siemes C, Jansman FGA, Kibbelaar RE, Veeger NJGM, Hoogendoorn M, van Roon EN. Oortgiesen BE, et al. Among authors: kroes ja. Support Care Cancer. 2022 Jan;30(1):271-278. doi: 10.1007/s00520-021-06414-3. Epub 2021 Jul 17. Support Care Cancer. 2022. PMID: 34273034 Free PMC article.

8

Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study.

Kroes JA, Zielhuis SW, van der Meer AN, de Jong K, Ten Brinke A, van Roon EN. Kroes JA, et al. Int J Clin Pharm. 2022 Apr;44(2):570-574. doi: 10.1007/s11096-021-01362-8. Epub 2021 Dec 1. Int J Clin Pharm. 2022. PMID: 34851505

9

Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma.

Kroes JA, Zielhuis SWJ, De Jong K, Hashimoto S, Sont JK, Zielhuis SW, Van Roon EN, Bel EH, Ten Brinke A; RAPSODI Team. Kroes JA, et al. Eur Respir J. 2022 Nov 3;60(5):2102983. doi: 10.1183/13993003.02983-2021. Print 2022 Nov. Eur Respir J. 2022. PMID: 35595317 Free PMC article.

10

Reply to "Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma".

Eger K, Kroes JA, Ten Brinke A, Bel EH. Eger K, et al. Among authors: kroes ja. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1936. doi: 10.1016/j.jaip.2022.04.018. J Allergy Clin Immunol Pract. 2022. PMID: 35809997 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page